Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USAAbstract: Lasofoxifene is a selective estrogen receptor modulator (estrogen agonist/antagonist) that has completed phase III trials to evaluate safety and efficacy for the prevention and treatm...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2009-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |